CLDN18 and neoplasm: Conversely, in patients with CLDN18.2 expression in 40–69% of tumor cells, PFS (4.3 vs. 4.1 months, HR 0.71, 95% CI: 0.32–1.57, p = 0.497) and OS (8.3 vs. 7.4 months, HR 0.78, 95% CI: 0.40–1.49, p = 0.401) were not significantly different.